FDA approves GILOTRIF™ (afatinib) as first-line treatment for metastatic non-small cell lung cancer with common EGFR mutations

FDA approves GILOTRIF™ (afatinib) as first-line treatment for metastatic non-small cell lung cancer with common EGFR mutations

Submitted by admin on July 13, 2013 - 12:37pm
Source: 
Sacramento Bee, CA
News Tags: 
non-small cell lung cancer
Gilotrif
Afatinib
Boehringer Ingelheim
Headline: 
FDA approves GILOTRIF™ (afatinib) as first-line treatment for metastatic non-small cell lung cancer with common EGFR mutations

Do Not Allow Advertisers to Use My Personal information